Dogwood Therapeutics (DWTX) Corporate presentation summary

Corporate overview and pipeline

• Headquarters in Atlanta, GA, listed on Nasdaq with 33.6M shares outstanding and $13.2M cash as of March 31, 2026.

• Pipeline includes Halneuron® (acquired Q4 2024) and SP16 (licensed Q4 2025), with out-licensing of IMC-1/IMC-2 in Q2 2026.

• Analyst coverage by H.C. Wainwright and Maxim Group.

Leadership and expertise

• Executive team with proven drug development and commercial success, including experience with Zoloft, Viagra, Lipitor, and Lyrica.

Market opportunity and unmet need

• Over 3 million US patients suffer from chemotherapy-induced neuropathic pain (CINP), with 300,000+ new cases annually.

• No FDA-approved therapies for CINP; current treatments are largely ineffective, representing a $3B US market opportunity.

• Halneuron® targets the Nav1.7 sodium channel, aiming to treat moderate to severe CINP.